<DOC>
	<DOC>NCT01262638</DOC>
	<brief_summary>This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Major Provision of written informed consent prior to any studyspecific procedure Fasting LDLC between 130 and 220 mg/dL following washout of all lipid regulating medications and supplements Fasting triglyceride &lt;400 mg/dL following washout of all lipid regulating medications and supplements BMI between 18 and 35 mg/kg2 Major Clinically significant cardiovascular disease, diabetes or uncontrolled hypertension Females of child bearing potential (i.e., females who are not surgically sterile or postmenopausal)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>